Adagio Medical Holdings (ADGM) KOL event summary

Introduction and agenda

• The event focused on presenting and discussing results from the FULCRUM-VT pivotal study for monomorphic ventricular tachycardia, recently highlighted at a major scientific conference.

• Event focused on the FULCRUM-VT pivotal trial evaluating ultra-low temperature cryoablation for ventricular tachycardia in structural heart disease patients.

• Presented at Heart Rhythm Society 2026, with key investigators sharing trial design, results, and future directions.

• The session included presentations, panel discussions, and a Q&A with leading electrophysiologists.

KOL background and credentials

• Dr. Verma is a Professor at McGill, Director of Cardiology, and principal investigator for FULCRUM-VT, with expertise in arrhythmia ablation and clinical trials.

• Dr. Stevenson, Professor at Vanderbilt, is a leader in cardiac arrhythmia management and cardiac mapping, and was the top enroller in the study.

• Dr. Hakimi, Medical Director and practicing electrophysiologist, contributed clinical and product development insights.

• Dr. Atul Verma: Research grants from major device companies, advisory roles, and clinical trial leadership.

• Dr. William Stevenson: Honoria and research support from leading medical device firms.

Market insights and analysis

• VT ablation has been limited by inadequate depth and complications with existing technologies, especially in scarred or thick ventricular tissue.

• Current ablation methods lack sufficient lesion depth and universal applicability for both ischemic and non-ischemic cardiomyopathy.

• Ultra-low temperature ablation (ULTA) offers deeper, more consistent lesions without irrigation, reducing fluid overload and complications.

• Ultra-low temperature ablation offers large, depth-controlled lesions unaffected by scar tissue.

• The technology is seen as a potential first-line tool for a broad range of VT patients, including those with non-ischemic cardiomyopathy.